HOME >> BIOLOGY >> NEWS
A Protein Switch May Turn On Heart Cells To Combat Heart Disease

DALLAS, Nov. 8 -- Scientists are finding ways to switch on and off key proteins that may make heart cells come out of biological "dormancy" and replace the damaged cells that result from heart disease. Their research was reported today in two presentations at the American Heart Association's 71st Scientific Sessions.

Unlike most other cells in the body, heart muscle cells, called myocytes, are believed to stop multiplying shortly after birth and do not regenerate, even if they are damaged, say the researchers. Because heart muscle cells can not generate new cells, they enlarge to accommodate growth of the heart and to take over the functioning of cells damaged by a heart attack or other conditions, such as high blood pressure, that stress the heart.

"After a heart attack, or in response to stresses on the heart, myocytes will get bigger. However, these bigger heart cells don't work as well," says W. Robb MacLellan, M.D., assistant professor in the Cardiovascular Research Laboratories at the University of California at Los Angeles School of Medicine.

"We're trying to find a way to get the cells to multiply instead of enlarge," he says. Cells that enlarge cause a condition known as left-ventricular hypertrophy, which can increase the risk of developing congestive heart failure.

MacLellan and colleagues say the research may lead to new "gene therapy" to treat heart enlargement and improve heart function in people who have heart disease.

Based on an earlier study suggesting that the "retinoblastoma" gene was critical in controlling cell division, MacLellan and his colleagues focused on the protein that this gene produces retinoblastoma protein, called Rb. Scientists believe the Rb protein may help keep heart cells "dormant" so they no longer can divide. To test this theory, MacLellan's group "turned off" the Rb in a group of mice. Researchers compared heart sizes between the genetically altered mice and mice who still had the Rb gene o
'"/>

Contact: Carole Bullock
caroleb@heart.org
214-706-1279
American Heart Association
8-Nov-1998


Page: 1 2

Related biology news :

1. Protein is key to fatal disorder and normal cell function
2. Protein is key for digestive function of the pancreas
3. Proteins show promise for mosquito control
4. Protein involved in childhood disorder linked to cancer
5. Protein fishing in America: The movie
6. Protein vaccine fully protects mice from lethal aerosol challenge with ricin toxin
7. Protein key to trafficking in nerve terminals
8. Protein controls acid in cells by direct detection of volume changes, study finds
9. Protein believed to control formation of memory identified by Scripps & UCSD scientists
10. Protein stops blood-vessel growth, holds promise as cancer therapy
11. Proteins transform DNA into molecular velcro

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Protein Switch May Turn Heart Cells Combat Heart Disease

(Date:5/21/2013)... largest gathering of biomass experts , Where? ... When? 03-07 June 2013 , ... research, resource assessment, market and policy developments, manufacturing and ... world and benefiting from its 2013 edition from a ... than 60 countries, more than 240 plenary and oral ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
(Date:5/20/2013)... the effect of physical education (PE) on child weight, ... increasing the amount of time that elementary schoolchildren spent ... The study represents some of the first evidence of ... is forthcoming in the Journal of Health Economics ... can be viewed at: http://www.sciencedirect.com/science/article/pii/S0167629613000556 , The ...
Breaking Biology News(10 mins):21st European Biomass Conference and Exhibition 221st European Biomass Conference and Exhibition 321st European Biomass Conference and Exhibition 4Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Gym class reduces probability of obesity, study finds for first time 2
(Date:5/21/2013)... Wisc. (PRWEB) May 21, 2013 ... parts distributor , will be exhibiting for the ... Advancement of Medical Instrumentation (AAMI) 2013 Conference and ... purchase, support, distribute, and manufacture healthcare technologies. This ... in Long Beach, California. , The three-day ...
(Date:5/21/2013)... NC (PRWEB) May 21, 2013 ... financial services company for clinical trials, announced today ... Spend Solutions, LLC. Clinverse’s ClinPay® FLS eClinical ... investigator payment process. SpendMD ™, Aggregate ... complete solution for tracking and reporting transfer of ...
(Date:5/21/2013)... Canada (PRWEB) May 21, 2013 ... is a strong push within the industry to ... and Manufacturing Organizations and pharma companies often means ... frames. , Microtablets, developed in collaboration with Sensidose ... effective outsourcing can bring products to market sooner. ...
(Date:5/21/2013)... , May 21, 2013  MacroGenics, Inc. today ... of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody ... the HER2 oncoprotein," will be presented at the ... Clinical Oncology during the Developmental Therapeutics - Immunotherapy ... 4:15 – 4:30 PM.  The presentation will describe ...
Breaking Biology Technology:Alpha Source, Inc. to Exhibit at the AAMI 2013 Conference and Expo 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 2Clinverse, Inc. Announces Strategic Alliance with Aggregate Spend Solutions, LLC 3The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 2MacroGenics Announces Margetuximab (MGAH22) Phase 1 Data Presentation at ASCO; Initiates Phase 2 Clinical Study to Evaluate Activity of Margetuximab in Patients with Metastatic Breast Cancer 3
Cached News: